These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31975354)

  • 81. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    ; Büller HR; Prins MH; Lensin AW; Decousus H; Jacobson BF; Minar E; Chlumsky J; Verhamme P; Wells P; Agnelli G; Cohen A; Berkowitz SD; Bounameaux H; Davidson BL; Misselwitz F; Gallus AS; Raskob GE; Schellong S; Segers A
    N Engl J Med; 2012 Apr; 366(14):1287-97. PubMed ID: 22449293
    [TBL] [Abstract][Full Text] [Related]  

  • 82. [EINSTEIN CHOICE: Comparison of rivaroxaban treatment and prophylactic doses with aspirin in the extended treatment of patients with venous thromboembolism].
    Kaymaz C
    Turk Kardiyol Dern Ars; 2017 Sep; 45(Suppl 4):1-7. PubMed ID: 28947723
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Relative effects of two different enoxaparin regimens as comparators against newer oral anticoagulants: meta-analysis and adjusted indirect comparison.
    Kwok CS; Pradhan S; Yeong JK; Loke YK
    Chest; 2013 Aug; 144(2):593-600. PubMed ID: 23519234
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Clinical Outcomes and Costs of Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Inpatients: A Cross-Sectional Study.
    Lenci Marques G; De Franca AC; Saito AC; Hornung FL; Motter AC; Falzoni Pontello AC; Fontana H; Gasparetto J; Zequinão T
    Cureus; 2021 Jun; 13(6):e15497. PubMed ID: 34268028
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Rivaroxaban versus enoxaparin for thromboprophylaxis in orthopedic surgery: A meta-analysis.
    Abad Vélaz O; Carbonel Bueno I
    Rev Esp Cir Ortop Traumatol; 2023 Sep; ():. PubMed ID: 37741360
    [TBL] [Abstract][Full Text] [Related]  

  • 86. External validation of the ADA score for predicting thrombosis among acutely ill hospitalized medical patients from the APEX Trial.
    Chi G; Violi F; Pignatelli P; Vestri A; Spagnoli A; Loffredo L; Hernandez AF; Hull RD; Cohen AT; Harrington RA; Goldhaber SZ; Gibson CM
    J Thromb Thrombolysis; 2023 Feb; 55(2):211-221. PubMed ID: 36566304
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Is Rivaroxaban Superior to Enoxaparin for Thromboprophylaxis in Hospitalized Patients of COVID-19?`.
    Deokar K; Kaliya M; Vachhani K; Singhal S; Parekh A
    J Assoc Physicians India; 2022 Sep; 70(9):11-12. PubMed ID: 36082899
    [No Abstract]   [Full Text] [Related]  

  • 88. Rivaroxaban Prophylaxis in Noncirrhotic Portal Vein Thrombosis.
    Plessier A; Goria O; Cervoni JP; Ollivier I; Bureau C; Poujol-Robert A; Minello A; Houssel-Debry P; Rautou PE; Payancé A; Scoazec G; Bruno O; Corbic M; Durand F; Vilgrain V; Paradis V; Boudaoud L; de Raucourt E; Roy C; Gault N; Valla D
    NEJM Evid; 2022 Dec; 1(12):EVIDoa2200104. PubMed ID: 38319842
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Thromboprophylaxis with rivaroxaban in patients with malignancy and central venous lines (TRIM-Line): A two-center open-label pilot randomized controlled trial.
    Ikesaka R; Siegal D; Mallick R; Wang TF; Witham D; Webb C; Carrier M;
    Res Pract Thromb Haemost; 2021 May; 5(4):e12517. PubMed ID: 34027291
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Dosing Regimen Prediction and Confirmation With Rivaroxaban for Thromboprophylaxis in Children After the Fontan Procedure: Insights From the Phase III UNIVERSE Study.
    Zhu P; Willmann S; Zhou W; Yang H; Michelson AD; McCrindle BW; Li JS; Harris KC; Pina LM; Weber T; Nessel K; Lesko LJ; Kubitza D; Zannikos P
    J Clin Pharmacol; 2022 Feb; 62(2):220-231. PubMed ID: 34524700
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Model-informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients aged 9 years and older with congenital heart disease.
    Willmann S; Ince I; Ahsman M; Coboeken K; Zhang Y; Thelen K; Kubitza D; Zannikos P; Zhou W; Pina LM; Post T; Lippert J
    CPT Pharmacometrics Syst Pharmacol; 2022 Aug; 11(8):1111-1121. PubMed ID: 35665486
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Rivaroxaban thromboprophylaxis for gastric/gastroesophageal junction tumors versus other tumors: A post hoc analysis of the randomized CASSINI trial.
    Mones JV; Streiff MB; Khorana AA; Bendheim GA; Damaraju CV; Wildgoose P; Burton P; Riess H; Soff GA
    Res Pract Thromb Haemost; 2021 Jul; 5(5):e12549. PubMed ID: 34308096
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Renal function and thromboprophylaxis in critically ill patients.
    Scholey GM; Saayman AG; Hingston CD; Wise MP
    Crit Care; 2010; 14(3):416. PubMed ID: 20497594
    [No Abstract]   [Full Text] [Related]  

  • 94. Identifying acutely ill medical patients requiring thromboprophylaxis.
    Chopard P; Spirk D; Bounameaux H
    J Thromb Haemost; 2006 Apr; 4(4):915-6. PubMed ID: 16634771
    [No Abstract]   [Full Text] [Related]  

  • 95. Model-Based Risk Prediction of Rivaroxaban with Amiodarone for Moderate Renal Impaired Elderly Population.
    Wang Z; Cheong EJY; Kojodjojo P; Chan ECY
    Cardiovasc Drugs Ther; 2023 Jun; 37(3):605-609. PubMed ID: 34705149
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Negative effects of rivaroxaban observed in a patient with multiple common risks triggered by a bicycle accident.
    Abe K; Momo K; Oto Y; Kida M; Iwakiri T; Tanaka K; Sasaki T
    Clin Case Rep; 2023 Jan; 11(1):e6748. PubMed ID: 36698524
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients.
    Spyropoulos AC; Ageno W; Albers GW; Elliott CG; Halperin JL; Hiatt WR; Maynard GA; Steg PG; Weitz JI; Lu W; Spiro TE; Barnathan ES; Raskob GE
    J Am Coll Cardiol; 2020 Jun; 75(25):3140-3147. PubMed ID: 32586587
    [TBL] [Abstract][Full Text] [Related]  

  • 98. New Paradigms of Extended Thromboprophylaxis in Medically Ill Patients.
    MacDougall K; Spyropoulos AC
    J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32252423
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease.
    Weir MR; Ashton V; Moore KT; Shrivastava S; Peterson ED; Ammann EM
    Am Heart J; 2020 May; 223():3-11. PubMed ID: 32112872
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Rivaroxaban in Peripheral Artery Disease after Revascularization.
    Bonaca MP; Bauersachs RM; Anand SS; Debus ES; Nehler MR; Patel MR; Fanelli F; Capell WH; Diao L; Jaeger N; Hess CN; Pap AF; Kittelson JM; Gudz I; Mátyás L; Krievins DK; Diaz R; Brodmann M; Muehlhofer E; Haskell LP; Berkowitz SD; Hiatt WR
    N Engl J Med; 2020 May; 382(21):1994-2004. PubMed ID: 32222135
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.